Table 3.
Incidence of adverse events immediately before three assessment points of health utility and HRQOL
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Interval, days [median (IQR)]a | |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 565 (99.3) | – | – | 4 (0.7) | 0 (0.0) | 23 (10–41) |
| Fever | 567 (99.6) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 23 (3–42) |
| Fatigue | 402 (70.7) | 150 (26.4) | 15 (2.6) | 2 (0.4) | 0 (0.0) | 27 (19–36) |
| Alopecia | 364 (64.0) | 63 (11.1) | 142 (25.0) | – | – | 21 (15–28) |
| Allergy | 563 (98.9) | 5 (0.9) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 21 (21–35) |
| Diarrhea | 511 (89.8) | 46 (8.1) | 12 (2.1) | 0 (0.0) | 0 (0.0) | 21 (14–33) |
| Oral mucositis | 521 (91.6) | 45 (7.9) | 3 (0.5) | 0 (0.0) | 0 (0.0) | 25 (15–41) |
| Nausea | 511 (89.8) | 52 (9.1) | 6 (1.1) | 0 (0.0) | 0 (0.0) | 28 (20–40) |
| Vomiting | 559 (98.2) | 9 (1.6) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 28 (17–35) |
| Anorexia | 468 (82.2) | 92 (16.2) | 9 (1.6) | 0 (0.0) | 0 (0.0) | 28 (19–41) |
| Edema | 497 (87.3) | 50 (8.8) | 21 (3.7) | 1 (0.2) | 0 (0.0) | 24 (21–28) |
| Motor neuropathy | 556 (97.7) | 12 (2.1) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 21 (14–28) |
| Sensory neuropathy | 433 (76.1) | 107 (18.8) | 27 (4.7) | 2 (0.4) | 0 (0.0) | 24 (18–28) |
| Arthralgia | 519 (91.2) | 47 (8.3) | 3 (0.5) | 0 (0.0) | 0 (0.0) | 21 (21–28) |
| Myalgia | 534 (93.8) | 29 (5.1) | 6 (1.1) | 0 (0.0) | 0 (0.0) | 21 (18–28) |
Data are expressed as n (%) unless otherwise specified
Percentage was calculated as the number of incidences divided by the number of total assessments of EQ-5D-3L or EORTC QLQ-C30 (569 assessments) at three assessment points. Multiple incidences in one patient were counted separately
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, HRQOL health-related quality of life, IQR interquartile range
aInterval between incidence date of grade 1 or higher adverse events and assessment date of health utility and HRQOL